Article Text

PDF
ACE inhibitors: back to prime time?
  1. Milan Gupta1,
  2. Subodh Verma2,
  3. G B John Mancini3
  1. 1Division of Cardiology, William Osler Health Centre, McMaster University, Hamilton, Canada
  2. 2Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Toronto, Canada
  3. 3Division of Cardiology, University of British Columbia, Vancouver, Canada
  1. Correspondence to:
    Dr S Verma
    Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, Canada, M5B 1W8; subodh.verma{at}sympatico.ca

Abstract

See articles on pages 1026 and 1081

  • CV, cardiovascular
  • EMEA, European Medicines Evaluation Agency
  • FDA, Federal Drug Agency
  • MI, myocardial infarction
  • cost–benefit analysis
  • hypertension
  • cardiovascular diseases
  • ACE inhibitors

Statistics from Altmetric.com

Footnotes

  • Conflict of interest: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles